Dr. Yves Joseph Ribeill, Ph.D., is currently a Partner and Entrepreneur in Residence with Argobio Studio based in Paris, France. Prior to that, he founded Scynexis, Inc. He served as its President from November 1999 to July 2015 and as Chief Executive Officer from November 1999 to April 1, 2015. In 2000, Ribeill served in various positions during the 20 years of his international career with Rhone-Poulenc, Aventis including Director of Chemistry for the Anti-Infective Group.
He was involved in all phases of the drug discovery and development effort that resulted in the FDA approval of multiple drugs at Rhone-Poulenc and Scynexis. He has been a Director of various Biotech companies in Europe and in the US. Ribeill is member of the Scientific Advisory board of DNDi. He was a member of the Scientific Advisory Committee of the World Health Organization and of the Medicine Malaria Venture in Geneva. He is the author of more than 26 publications and 15 patents. Ribeill has a Ph.D. in Chemistry from the University of Montpellier, France.